Evidence map›Paper›PMID 26061668›Full record

ReviewAIDS patient care and STDs2015

Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward.

Ying-Ru Lo, Carissa Chu, Jintanat Ananworanich, Jean-Louis Excler, Joseph D Tucker

Open access · hybridAbstract readReview
In one paragraph

Review in AIDS patient care and STDs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 4 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Ying-Ru Lo1 HIV, Hepatitis and STI Unit, World Health Organization , Regional Office for the Western Pacific, Manila, The Philippines .
Carissa Chu2 University of California San Francisco School of Medicine , San Francisco, California.
Jintanat Ananworanich4 US Military HIV Research Program , Bethesda, Maryland.
Jean-Louis Excler4 US Military HIV Research Program , Bethesda, Maryland.
Joseph D Tucker3 University of North Carolina Project-China , Guangzhou, P.R. China .
Henry M. Jackson Foundation · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · USWorld Health Organization - Pakistan · PK

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Unintended and Intended Implications of HIV Cure: A Social and Ethical AnalysisR01AI108366 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RENNIE, STUART, TUCKER, JOSEPH DAVID · 2013 to 2017
$2.9M
NIAID NIH HHS P30 AI050410NIAID NIH HHS P30-AI50410NIAID NIH HHS R01 AI108366PHS HHS R01A108366-01World Health Organization 001
6 · The paper itself

Abstract

Clinical and basic science advances have raised considerable hope for achieving an HIV cure by accelerating research. This research is dominated primarily by issues about the nature and design of current and future clinical trials. Stakeholder engagement for HIV cure remains in its early stages. Our analysis examines timing and mechanisms of historical stakeholder engagement in other HIV research areas for HIV-uninfected individuals [vaccine development and pre-exposure prophylaxis (PrEP)], and HIV-infected individuals (treatment as prevention, prevention of mother-to-child transmission, and treatment of acute HIV infection) and articulate a plan for HIV cure stakeholder engagement. The experience from HIV vaccine development shows that early engagement of stakeholders helped manage expectations, mitigating the failure of several vaccine trials, while paving the way for subsequent trials. The relatively late engagement of HIV stakeholders in PrEP research may partly explain some of the implementation challenges. The treatment-related stakeholder engagement was strong and community-led from the onset and helped translation from research to implementation. We outline five steps to initiate and sustain stakeholder engagement in HIV cure research and conclude that stakeholder engagement represents a key investment in which stakeholders mutually agree to share knowledge, benefits, and risk of failure. Effective stakeholder engagement prevents misconceptions. As HIV cure research advances from early trials involving subjects with generally favorable prognosis to studies involving greater risk and uncertainty, success may depend on early and deliberate engagement of stakeholders.

Indexed as

Pre-Exposure ProphylaxisAIDS VaccinesAnti-HIV AgentsCommunity ParticipationHIV InfectionsHumansResearchAIDS VaccinesAnti-HIV Agents

Identifiers

PMID26061668
PMCPMC4504439
OpenAlexW2415892860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.